MA27435A1 - DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH - Google Patents

DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH

Info

Publication number
MA27435A1
MA27435A1 MA28148A MA28148A MA27435A1 MA 27435 A1 MA27435 A1 MA 27435A1 MA 28148 A MA28148 A MA 28148A MA 28148 A MA28148 A MA 28148A MA 27435 A1 MA27435 A1 MA 27435A1
Authority
MA
Morocco
Prior art keywords
hiv
pyrazole derivatives
modulators
dicyanophenoxy
enzyme
Prior art date
Application number
MA28148A
Other languages
English (en)
Inventor
Charles Eric Mowbary
David Anthony Price
Matthew Duncan Selby
Paul Anthony Stupple
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA27435A1 publication Critical patent/MA27435A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/29—Saturated compounds containing keto groups bound to rings
    • C07C49/293—Saturated compounds containing keto groups bound to rings to a three- or four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/29—Saturated compounds containing keto groups bound to rings
    • C07C49/327—Saturated compounds containing keto groups bound to rings containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DEPOSANT Société dite : PFIZER INC. REVENDICATION DE PRIORITES GB 16 Septembre 2002 0221477.3 GB 8 Octobre 2002 0223354.2 Voir en annexe le titre de l'invention et le texte de 1'abrégé Dérivés de 4-(3,5-dicyanophénoxy)pyrazole destinés à être utilisés comme modulateurs de transcriptase dans le traitement d'affections provoquées par le VIH La présente invention concerne les dérivés de pyrazole de formule (I) et leurs sels, produits de solvatation ou dérivés pharmaceutiquement acceptables, leur utilisation en médecine, des compositions les contenant, des procédés pour leur préparation et les intermédiaires utilisés dans ces procédés. Les composés de la présente invention se lient à l'enzyme consistant en transcriptase inverse et sont des modulateurs, notamment des inhibiteurs, de cette enzyme. La transcriptase inverse est impliquée dans le cycle vital infectieux du virus d'immunodéficience humaine (VIH) . Des composés qui interfèrent avec la fonction de cette enzyme se sont révélés être utiles dans le traitement d'affections provoquées par le VIH et des rétrovirus génétiquement apparentés, telles que le syndrome d'immunodéficience acquise (SIDA).
MA28148A 2002-09-16 2005-03-16 DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH MA27435A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0221477.3A GB0221477D0 (en) 2002-09-16 2002-09-16 Chemical compounds
GBGB0223354.2A GB0223354D0 (en) 2002-09-16 2002-10-08 Chemical compounds

Publications (1)

Publication Number Publication Date
MA27435A1 true MA27435A1 (fr) 2005-07-01

Family

ID=31995706

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28148A MA27435A1 (fr) 2002-09-16 2005-03-16 DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH

Country Status (20)

Country Link
EP (1) EP1542679B1 (fr)
JP (1) JP2006504792A (fr)
KR (1) KR20050043962A (fr)
CN (1) CN1681494A (fr)
AP (1) AP2005003248A0 (fr)
AU (1) AU2003263422A1 (fr)
BR (1) BR0314243A (fr)
CA (1) CA2496315A1 (fr)
DE (1) DE60311284T2 (fr)
EA (1) EA200500287A1 (fr)
EC (1) ECSP055673A (fr)
GB (2) GB0221477D0 (fr)
HR (1) HRP20050222A2 (fr)
IS (1) IS7705A (fr)
MA (1) MA27435A1 (fr)
MX (1) MXPA05002963A (fr)
NO (1) NO20051833L (fr)
OA (1) OA12920A (fr)
PL (1) PL375976A1 (fr)
WO (1) WO2004024147A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100322A1 (fr) * 2004-04-14 2005-10-27 Pfizer Limited Composes d'imidazole a liaison souphre pour le traitement du vih
DE102008015033A1 (de) * 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3303200A (en) * 1963-11-05 1967-02-07 American Home Prod Pyrazole-1-ethanol derivatives
GB0016787D0 (en) * 2000-07-07 2000-08-30 Pfizer Ltd Compounds useful in therapy
EE05400B1 (et) * 2001-04-10 2011-04-15 Pfizer Inc. Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks

Also Published As

Publication number Publication date
IS7705A (is) 2005-02-21
AU2003263422A1 (en) 2004-04-30
OA12920A (en) 2006-10-13
GB0223354D0 (en) 2002-11-13
JP2006504792A (ja) 2006-02-09
GB0221477D0 (en) 2002-10-23
EP1542679A1 (fr) 2005-06-22
CN1681494A (zh) 2005-10-12
NO20051833L (no) 2005-06-14
HRP20050222A2 (en) 2005-10-31
DE60311284D1 (de) 2007-03-08
PL375976A1 (en) 2005-12-12
MXPA05002963A (es) 2005-05-27
EP1542679B1 (fr) 2007-01-17
ECSP055673A (es) 2005-07-06
EA200500287A1 (ru) 2005-10-27
WO2004024147A1 (fr) 2004-03-25
BR0314243A (pt) 2005-07-26
CA2496315A1 (fr) 2004-03-25
DE60311284T2 (de) 2007-06-21
KR20050043962A (ko) 2005-05-11
AP2005003248A0 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
MA27009A1 (fr) Derives de pyrazole pour le traitement d'une infection par le vih
MA27990A1 (fr) Derives de piperazine pour le traitement d'infections par le vih
MA27647A1 (fr) Antagonistes de ccr5 utiles comme agents therapeutiques
MA28747B1 (fr) Dérivés de pyridine
MA27444A1 (fr) Derives d'isothiazole et d'isoxazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27443A1 (fr) Oxazoles et thiazoles nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27442A1 (fr) Derives de triazole servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA29926B1 (fr) Derives de pyrazine
MA27840A1 (fr) Derives de (2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propylphenyle servant d'agonistes beta2
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA26861A1 (fr) Inhibiteurs non peptidiques de la liaison cellulaire sous la dependance de vla-4 utiles dans le traitement des maladies inflammatoires, auto-immunes et respiratoires
MA27174A1 (fr) Derives de nicotinamide utiles comme inhibiteurs de pde4.
MA26946A1 (fr) Derives de pyrazole nouveaux et leur utilisation comme inhibiteurs de proteine-kinases.
MA27440A1 (fr) Derives de pyrazole servant d'inhibiteurs du facteur de croissance transformant(tgf)
MA27441A1 (fr) Composes d'imidazole nouveaux servant d'inhibiteurs du facteur de croissance transformant (tgf)
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA27348A1 (fr) Inhibiteurs de protease du vih, compositions les contenant, leurs utilisations pharmaceutiques et matieres pour leur synthese
MA49956B1 (fr) Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
MA27435A1 (fr) DERIVES DE 4-(3,5-DICYANOPHENOXY) PYRAZOLE DESTINES A eTRE UTILISES COMME MODULATEURS DE TRANSCRIPTASE DANS LE TRAITEMENT D'AFFECTIONS PROVOQUEES PAR LE VIH
DE60318874D1 (en) Pyrazolderivate
MA57000B1 (fr) Dérivés d'alpha-d-galactopyranoside
MA30924B1 (fr) Analogues de pyrazoles
TNSN05072A1 (fr) Derives de 4-(3,5-dicyanophenoxy) pyrazole destines a etre utilises comme modulateurs de transcriptase dans le traitement d'affections provoquees par le vih
BR0314759A (pt) Derivados de pirazol